Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS1701
- Development stage
- Preclinical
- Lead developer
- Zhongke Aishen Pharmaceutical
01
Overview
AS1701 is a preclinical-stage biologic blocker developed by Zhongke Aishen Pharmaceutical (Amshenn) that targets the Rel immune checkpoint. Positioned as a next-generation successor to the company's AS1601 program, AS1701 is designed to inhibit Rel-mediated immunosuppression within the tumor microenvironment. The agent is intended for the treatment of solid tumors, either as a standalone therapy or in combination with PD-1 blockade to overcome resistance and improve clinical outcomes. It is currently in the efficacy exploration stage of development.
- Other names
- Rel blocker
Beyond the preview
Go deeper on AS1701.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AS1701.